- Home
- OMI vs KURA Comparison
OMI vs KURA Comparison
Compare OMI & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMI
- KURA
- Stock Information
- Founded
- OMI 1882
- KURA 2014
- Country
- OMI United States
- KURA United States
- Employees
- OMI N/A
- KURA N/A
- Industry
- OMI Medical Specialities
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OMI Health Care
- KURA Health Care
- Exchange
- OMI Nasdaq
- KURA Nasdaq
- Market Cap
- OMI 545.4M
- KURA 492.9M
- IPO Year
- OMI N/A
- KURA N/A
- Fundamental
- Price
- OMI $7.61
- KURA $6.57
- Analyst Decision
- OMI Hold
- KURA Strong Buy
- Analyst Count
- OMI 6
- KURA 12
- Target Price
- OMI $12.83
- KURA $24.50
- AVG Volume (30 Days)
- OMI 1.3M
- KURA 1.2M
- Earning Date
- OMI 08-01-2025
- KURA 05-01-2025
- Dividend Yield
- OMI N/A
- KURA N/A
- EPS Growth
- OMI N/A
- KURA N/A
- EPS
- OMI N/A
- KURA N/A
- Revenue
- OMI $10,720,251,000.00
- KURA $67,991,000.00
- Revenue This Year
- OMI $4.48
- KURA $109.86
- Revenue Next Year
- OMI $3.10
- KURA $107.97
- P/E Ratio
- OMI N/A
- KURA N/A
- Revenue Growth
- OMI 2.84
- KURA N/A
- 52 Week Low
- OMI $6.07
- KURA $5.41
- 52 Week High
- OMI $17.78
- KURA $23.48
- Technical
- Relative Strength Index (RSI)
- OMI 58.83
- KURA 58.34
- Support Level
- OMI $6.17
- KURA $5.56
- Resistance Level
- OMI $6.76
- KURA $5.84
- Average True Range (ATR)
- OMI 0.46
- KURA 0.36
- MACD
- OMI 0.07
- KURA 0.09
- Stochastic Oscillator
- OMI 61.80
- KURA 89.71
About OMI Owens & Minor Inc.
Owens & Minor Inc distributes consumable medical supplies to a variety of providers. The business is under two segments: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment manufactures and sources medical surgical products through its production and kitting operations and provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies. Majority of the revenue is generated from Products & Healthcare Services segment.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.